Amazon jumps 5% after AWS and OpenAI announce $38B partnership
Investing.com - Cantor Fitzgerald has reiterated its Neutral rating and $450.00 price target on Alnylam Pharmaceuticals (NASDAQ:ALNY), currently trading at $474 and near its 52-week high of $492.62, ahead of its upcoming third-quarter earnings report. According to InvestingPro analysis, the stock appears overvalued at current levels.
The firm notes significant investor attention is focused on Amvuttra’s third-quarter sales figures, which will be revealed on October 30. Following what Cantor describes as a "standout" second-quarter launch in ATTR-CM that generated $150 million in its first full quarter, market expectations have risen considerably. The company’s strong execution has contributed to an impressive 103.45% return over the past six months.
According to Cantor Fitzgerald, investors are generally anticipating more than $300 million in Amvuttra ATTR-CM revenue for the third quarter. These expectations continue to increase as Alnylam’s stock has shown strong performance leading up to the earnings announcement.
The research firm acknowledges Alnylam has "earned the benefit of the doubt" through its performance thus far. Cantor notes the company is "executing exceptionally well" on the Amvuttra cardiomyopathy launch.
All indicators point to "continued commercial momentum" for Amvuttra in the second half of 2025, according to the Cantor Fitzgerald analysis. With a market cap of $62.13 billion and an overall "GOOD" financial health rating from InvestingPro, which offers 13 additional valuable insights about ALNY, the company maintains a strong position in the market.
In other recent news, Alnylam Pharmaceuticals reported strong first-quarter performance, driven by exceptional sales of Vutrisiran, leading Stifel to raise its price target for the company to $495.00 while maintaining a Buy rating. This drug, which treats transthyretin-mediated amyloidosis (ATTR), showed promising results by reducing gastrointestinal events in patients by up to 49%, according to new analyses from the HELIOS-B Phase 3 study. Meanwhile, H.C. Wainwright reaffirmed its Buy rating with a $570.00 price target, highlighting the potential benefits Alnylam could gain from the FDA’s draft guidances on clinical trial design and real-world evidence. Wells Fargo maintained its Equal Weight rating with a price target of $395.00, indicating a neutral stance on the company’s prospects.
Additionally, Alnylam has pulled a television advertisement for its heart medicine Amvuttra following a warning letter from the FDA, which deemed the commercial misleading. The FDA’s scrutiny came after the ad depicted patients engaging in activities such as whale-watching and cheering at football games. These developments reflect a dynamic period for Alnylam Pharmaceuticals, with significant attention from both regulatory bodies and investment firms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.